CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

Background Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with clopidogrel after percutaneous coronary intervention (PCI). We sought to evaluate real‐world outcomes with the clinical implementat...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Amber L. Beitelshees, Cameron D. Thomas, Philip E. Empey, George A. Stouffer, Dominick J. Angiolillo, Francesco Franchi, Sony Tuteja, Nita A. Limdi, James C. Lee, Julio D. Duarte, Rolf P. Kreutz, Todd C. Skaar, James C. Coons, Jay Giri, Caitrin W. McDonough, Rachel Rowland, James M. Stevenson, Thuy Thai, Mark R. Vesely, Jacob T. Wellen, Julie A. Johnson, Almut G. Winterstein, Larisa H. Cavallari, Craig R. Lee
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2022-02-01
Serier:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Fag:	clopidogrel CYP2C19 pharmacogenetics
Online adgang:	https://www.ahajournals.org/doi/10.1161/JAHA.121.024159
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!